Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, Coles B, Trovato A. Polymorphisms in Genes Related to Oxidative Stress (MPO, MnSOD, CAT) and Survival After Treatment for Breast Cancer. Cancer Res 2005. [DOI: 10.1158/0008-5472.1105.65.3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

For:	Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, Coles B, Trovato A. Polymorphisms in Genes Related to Oxidative Stress (MPO, MnSOD, CAT) and Survival After Treatment for Breast Cancer. Cancer Res 2005. [DOI: 10.1158/0008-5472.1105.65.3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

Number

Cited by Other Article(s)

Erdman V, Tuktarova I, Nasibullin T, Timasheva Y, Petintseva A, Korytina G. Polygenic markers of survival and longevity in the antioxidant genes PON1, PON2, MTHFR, MSRA, SOD1, NQO1, and CAT in a 20-year follow-up study in the population from the Volga-Ural region. Gene 2024;919:148510. [PMID: 38679184 DOI: 10.1016/j.gene.2024.148510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Revised: 04/16/2024] [Accepted: 04/24/2024] [Indexed: 05/01/2024]

Abstract

BACKGROUND

Genetic background of healthy or pathological styles of aging and human lifespan is determined by joint gene interactions. Lucky combinations of antioxidant gene polymorphisms can result in a highly adaptive phenotype, providing a successful way to interact with external triggers. Our purpose was to identify the polygenic markers of survival and longevity in the antioxidant genes among elderly people with physiological and pathological aging.

METHODS

In a 20-year follow-up study of 2350 individuals aged 18-114 years residing in the Volga-Ural region of Russia, sex-adjusted association analyses of MTHFR rs1801133, MSRA rs10098474, PON1 rs662, PON2 rs7493, SOD1 rs2070424, NQO1 rs1131341 and CAT rs1001179 polymorphic loci with longevity were carried out. Survival analysis was subsequently performed using the established single genes and gene-gene combinations as cofactors.

RESULTS

The PON1 rs662*G allele was defined as the main longevity marker in women (OR = 1.44, p = 3E-04 in the log-additive model; HR = 0.77, p = 1.9E-04 in the Cox-survival model). The polymorphisms in the MTHFR, MSRA, PON2, SOD1, and CAT genes had an additive effect on longevity. A strong protective effect of combined MTHFR rs1801133*C, MSRA rs10098474*T, PON1 rs662*G, and PON2 rs7493*C alleles against mortality was obtained in women (HR = 0.81, p = 5E-03). The PON1 rs662*A allele had a meaningful impact on mortality for both long-lived men with cerebrovascular accidents (HR = 1.76, p = 0.027 for the PON1 rs662*AG genotype) and women with cardiovascular diseases (HR = 1.43, p = 0.002 for PON1 rs662*AA genotype). The MTHFR rs1801133*TT (HR = 1.91, p = 0.036), CAT rs1001179*TT (HR = 2.83, p = 0.031) and SOD1 rs2070424*AG (HR = 1.58, p = 0.018) genotypes were associated with the cancer mortality.

CONCLUSION

In our longitudinal 20-year study, we found the combinations of functional polymorphisms in antioxidant genes involved in longevity and survival in certain clinical phenotypes in the advanced age.

Collapse

Hua L, Zhang P, Liu H, Xin M, Zhang Z, Han D, Zhang Z, Zhu X, Jin J, Yang Y, Xie S. Effects of Dietary Inosine 5'-Monophosphate Supplementation on the Growth Performance and Salinity and Oxidative Stress Resistance of Gibel Carp (Carassius auratus gibelio). Antioxidants (Basel) 2024;13:487. [PMID: 38671934 PMCID: PMC11047338 DOI: 10.3390/antiox13040487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Revised: 04/10/2024] [Accepted: 04/11/2024] [Indexed: 04/28/2024] Open

Abstract

An 88-day feeding trial was conducted to evaluate the effects of dietary inosine 5'-monophosphate (5'-IMP) on the growth performance and salinity and oxidative stress resistance in the juvenile gibel carp CAS III (Carassius auratus gibelio; initial body weight: 7.48 g). Four isonitrogenous and isoenergetic diets containing exogenous 5'-IMP were formulated. P1, P2, P3 and P4 were diets containing 5'-IMP at four concentrations (0, 1, 2 and 4 g kg-1). The four diets were randomly allotted to triplicate tanks in a recirculating system. After the feeding trial, six fish per tank were netted randomly and placed into 12‱ saline water to test their response to salinity stress. The results indicated that the feed conversion rate was enhanced by dietary supplementation with 5'-IMP. The appetite, plasma neuropeptide Y level and feeding rate of the P3 group were lower than those in the control treatment group. Dietary supplementation with 5'-IMP improved the osmoregulatory adaptation of gibel carp under acute salinity stress. Six hours after the salinity stress treatment, in the dietary 5'-IMP treatment group, the plasma cortisol and K+ concentrations were lower and the Na+/K+-ATPase activity was greater than that in the control group. Dietary supplementation with 5'-IMP promoted the expression of the glucocorticoid receptors NKA-α1b and NKCC and retarded the expression of Hsp70 in P4-treated gill filaments and kidneys. Dietary supplementation with 5'-IMP resulted in a stable oxidative-stress-resistant phenotype characterized by increased levels of cellular antioxidants, including SOD, catalase, glutathione peroxidase, glutathione reductase and MPO. The above results of the current study demonstrate that supplementation of 5'-IMP can promote feed utilization and have positive influences on the salinity and oxidative stress resistance of gibel carp.

Collapse

Affiliation(s)

Luohai Hua Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.) University of Chinese Academy of Sciences, Beijing 100049, China
Peiyu Zhang Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.) University of Chinese Academy of Sciences, Beijing 100049, China
Haokun Liu Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.) Jiangxi Innovation and Incubation Center of Industrial Technologies, Chinese Academy of Sciences, Nanchang 330072, China Nanchang Institute of Industrial Innovation, Chinese Academy of Sciences, Nanchang 330072, China
Mingze Xin Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.) University of Chinese Academy of Sciences, Beijing 100049, China
Zhiwei Zhang Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.) University of Chinese Academy of Sciences, Beijing 100049, China
Dong Han Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.) University of Chinese Academy of Sciences, Beijing 100049, China Hubei Engineering Research Center for Aquatic Animal Nutrition and Feed, Wuhan 430072, China
Zhimin Zhang Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.)
Xiaoming Zhu Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.) Hubei Engineering Research Center for Aquatic Animal Nutrition and Feed, Wuhan 430072, China
Junyan Jin Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.)
Yunxia Yang Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.)
Shouqi Xie Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (L.H.); (P.Z.); (M.X.); (Z.Z.); (D.H.); (Z.Z.); (X.Z.); (J.J.); (Y.Y.); (S.X.) University of Chinese Academy of Sciences, Beijing 100049, China Hubei Engineering Research Center for Aquatic Animal Nutrition and Feed, Wuhan 430072, China The Innovative Academy of Seed Design, Chinese Academy of Sciences, Wuhan 430072, China

Collapse

Li J, Yin K, Hou L, Zhang Y, Lu H, Ma C, Xing M. Polystyrene microplastics mediate inflammatory responses in the chicken thymus by Nrf2/NF-κB pathway and trigger autophagy and apoptosis. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2023;100:104136. [PMID: 37127111 DOI: 10.1016/j.etap.2023.104136] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Revised: 03/15/2023] [Accepted: 04/28/2023] [Indexed: 05/03/2023]

Genetic polymorphism impact superoxide dismutase and glutathione peroxidase activity in charcoal workers. Mol Biol Rep 2022;49:10251-10257. [PMID: 36074229 DOI: 10.1007/s11033-022-07779-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Accepted: 07/06/2022] [Indexed: 10/14/2022]

Ustabas Kahraman F, Çakir FB, Buhur Pirimoglu M, Torun E, Ergen HA, Doğan Demir A. Association of Myeloperoxidase Gene Polymorphism With Iron Deficiency Anemia in Turkish Children. J Pediatr Hematol Oncol 2021;43:e941-e945. [PMID: 33661166 DOI: 10.1097/mph.0000000000002125] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Accepted: 01/21/2021] [Indexed: 11/26/2022]

Kalezic A, Udicki M, Srdic Galic B, Aleksic M, Korac A, Jankovic A, Korac B. Redox profile of breast tumor and associated adipose tissue in premenopausal women - Interplay between obesity and malignancy. Redox Biol 2021;41:101939. [PMID: 33765617 PMCID: PMC8008245 DOI: 10.1016/j.redox.2021.101939] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 03/04/2021] [Accepted: 03/06/2021] [Indexed: 12/13/2022] Open

Abstract

One of the underlying mechanisms that could link breast cancer and obesity is shifted redox homeostasis in the tumor microenvironment. To reveal the relationship between the malignant phenotype and obesity, we compared redox profiles of breast tumor and tumor-associated adipose tissue from premenopausal women: normal-weight with benign tumors, overweight/obese with benign tumors, normal-weight with malignant tumors, and overweight/obese with malignant tumors. Namely, we examined the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), protein expression and activity of main antioxidant defense (AD) enzymes: copper, zinc- and manganese superoxide dismutase, catalase, and glutathione peroxidase, as well as the level of 4-hydroxy-2-nonenal (4-HNE) modified proteins. Higher protein expression and activity of AD enzymes were found in malignant tumor tissue than benign tumor tissue, irrespective of obesity. Nevertheless, malignant tumor tissue of overweight/obese women was characterized by higher protein expression of Nrf2 and weaker immunopositivity for 4-HNE modified proteins. In malignant tumor-associated adipose tissue, the redox profile was clearly related to obesity. Higher Nrf2 protein expression and higher AD enzyme levels were observed in normal-weight women, while stronger immunopositivity for 4-HNE modified proteins was found in overweight/obese women. The results suggest that the complex interplay between obesity and malignancy involves redox-sensitive pathways in breast tumor and tumor-associated adipose tissue.

•

In malignant breast tumor tissue, antioxidant defense enzyme levels are not related to obesity.

•

In malignant tumor-associated adipose tissue, redox profile is related to obesity.

•

Nrf2 contributes to the “activated” phenotype of adipose tissue in malignancy.

Collapse

Liu B, Xiao X, Zhou X, Zhou J, Lan L, Long X, Pan Y, Du M, Zhao X. Effects of Lactobacillus plantarum CQPC01-fermented soybean milk on activated carbon-induced constipation through its antioxidant activity in mice. Food Sci Nutr 2019;7:2068-2082. [PMID: 31289655 PMCID: PMC6593386 DOI: 10.1002/fsn3.1048] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 04/01/2019] [Accepted: 04/07/2019] [Indexed: 01/30/2023] Open

Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng TYD, Chin SF, Clarke CL, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulias V, Giles GG, Glendon G, Goldgar DE, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko YD, Koppert LB, Kosma VM, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo WY, Loibl S, Lubiński J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Mavroudis D, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pinchev M, Prajzendanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott RJ, Scott C, Seynaeve C, Shah M, Simard J, Smeets A, Sohn C, Southey MC, Swerdlow AJ, Talhouk A, Tamimi RM, Tapper WJ, Teixeira MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer HU, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willett W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK. Genome-wide association study of germline variants and breast cancer-specific mortality. Br J Cancer 2019;120:647-657. [PMID: 30787463 PMCID: PMC6461853 DOI: 10.1038/s41416-019-0393-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Revised: 01/02/2019] [Accepted: 01/14/2019] [Indexed: 12/17/2022] Open

Affiliation(s)

Maria Escala-Garcia The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, The Netherlands
Qi Guo University of Cambridge, Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, Cambridge, UK.
Thilo Dörk Hannover Medical School, Gynaecology Research Unit, Hannover, Germany
Sander Canisius The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, The Netherlands The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Division of Molecular Carcinogenesis, Amsterdam, The Netherlands
Renske Keeman The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, The Netherlands
Joe Dennis University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
Jonathan Beesley QIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, Queensland, Australia
Julie Lecarpentier University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
Manjeet K Bolla University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
Qin Wang University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
Jean Abraham University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK Cambridge Experimental Cancer Medicine Centre, Cambridge, UK University of Cambridge NHS Foundation Hospitals, Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, Cambridge, UK
Irene L Andrulis Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, Canada University of Toronto, Department of Molecular Genetics, Toronto, ON, Canada
Hoda Anton-Culver University of California Irvine, Department of Epidemiology, Genetic Epidemiology Research Institute, Irvine, CA, USA
Volker Arndt German Cancer Research Center (DKFZ), Division of Clinical Epidemiology and Aging Research, Heidelberg, Germany
Paul L Auer Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Seattle, WA, USA University of Wisconsin-Milwaukee, Zilber School of Public Health, Milwaukee, WI, USA
Matthias W Beckmann University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany
Sabine Behrens German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany
Javier Benitez Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
Marina Bermisheva Ufa Scientific Center of Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia
Leslie Bernstein Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, CA, USA
Carl Blomqvist University of Helsinki, Department of Oncology, Helsinki University Hospital, Helsinki, Finland Örebro University Hospital, Department of Oncology, Örebro, Sweden
Bram Boeckx VIB, VIB Center for Cancer Biology, Leuven, Belgium University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium
Stig E Bojesen Copenhagen University Hospital, Copenhagen General Population Study, Herlevand Gentofte Hospital, Herlev, Denmark Copenhagen University Hospital, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark
Bernardo Bonanni Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS Milan, Milan, 20141, Italy
Anne-Lise Børresen-Dale Oslo University Hospital-Radiumhospitalet, Department of Cancer Genetics, Institute for Cancer Research, Oslo, Norway University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway Department of Research, Vestre Viken Hospital, Drammen, Norway; Section for Breast- and Endocrine Surgery, Department of Cancer, Division of Surgery, Cancer and Transplantation Medicine, Oslo University Hospital-Ullevål, Oslo, Norway Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway Department of Pathology at Akershus University hospital, Lørenskog, Norway Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway Department of Oncology, Division of Surgery and Cancer and Transplantation Medicine, Oslo University Hospital-Radiumhospitalet, Oslo, Norway National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway Department of Oncology, Akershus University Hospital, Lørenskog, Norway Breast Cancer Research Consortium, Oslo University Hospital, Oslo, Norway
Hiltrud Brauch Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany University of Tübingen, Tübingen, Germany German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
Hermann Brenner German Cancer Research Center (DKFZ), Division of Clinical Epidemiology and Aging Research, Heidelberg, Germany German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Division of Preventive Oncology, Heidelberg, Germany
Adam Brentnall Queen Mary University of London, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, UK
Louise Brinton National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
Per Broberg Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden
Ian W Brock University of Sheffield, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Sheffield, UK
Sara Y Brucker University of Tübingen, Department of Gynecology and Obstetrics, Tübingen, Germany
Barbara Burwinkel University of Heidelberg, Department of Obstetrics and Gynecology, Heidelberg, Germany German Cancer Research Center (DKFZ), Molecular Epidemiology Group, C080, Heidelberg, Germany
Carlos Caldas Cambridge Experimental Cancer Medicine Centre, Cambridge, UK University of Cambridge NHS Foundation Hospitals, Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, Cambridge, UK The Institute of Cancer Research, Section of Cancer Genetics, London, UK
Trinidad Caldés Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Medical Oncology Department, Hospital Cl'nico San Carlos, Madrid, Spain
Daniele Campa German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany University of Pisa, Department of Biology, Pisa, Italy
Federico Canzian German Cancer Research Center (DKFZ), Molecular Epidemiology Group, C080, Heidelberg, Germany
Angel Carracedo Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Genomic Medicine Group, Galician Foundation of Genomic Medicine, SERGAS, Santiago de Compostela, Spain Universidad de Santiago de Compostela, Centro de Investigación en Red de Enfermedades Raras (CIBERER), Santiago De Compostela, Spain King Abdulaziz University, Center of Excellence in Genomic Medicine, Jeddah, Kingdom of Saudi Arabia
Brian D Carter American Cancer Society, Epidemiology Research Program, Atlanta, GA, USA
Jose E Castelao Instituto de Investigación Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Oncology and Genetics Unit, Vigo, Spain
Jenny Chang-Claude German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), Hamburg, Germany
Stephen J Chanock National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
Georgia Chenevix-Trench QIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, Queensland, Australia
Ting-Yuan David Cheng Roswell Park Cancer Institute, Division of Cancer Prevention and Control, Buffalo, NY, USA
Suet-Feung Chin University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK
Christine L Clarke University of Sydney, Westmead Institute for Medical Research, Sydney, NSW, Australia
Emilie Cordina-Duverger INSERM, University Paris-Sud, University Paris-Saclay, Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), Villejuif, France
Fergus J Couch Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA
David G Cox Imperial College London, Department of Epidemiology and Biostatistics, School of Public Health, London, UK Cancer Research Center of Lyon, INSERM U1052, Lyon, France
Angela Cox University of Sheffield, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Sheffield, UK
Simon S Cross University of Sheffield, Academic Unit of Pathology, Department of Neuroscience, Sheffield, UK
Kamila Czene Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
Mary B Daly Fox Chase Cancer Center, Department of Clinical Genetics, Philadelphia, PA, USA
Peter Devilee Leiden University Medical Center, Department of Pathology, Leiden, The Netherlands Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands
Janet A Dunn University of Warwick, Warwick Clinical Trials Unit, Coventry, UK
Alison M Dunning University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
Lorraine Durcan University of Southampton, Southampton Clinical Trials Unit, Faculty of Medicine, Southampton, UK University of Southampton, Cancer Sciences Academic Unit, Faculty of Medicine, Southampton, UK
Miriam Dwek University of Westminster, Department of Biomedical Sciences, Faculty of Science and Technology, London, UK
Helena M Earl University of Cambridge NHS Foundation Hospitals, Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, Cambridge, UK University of Cambridge, Department of Oncology, Cambridge, UK
Arif B Ekici Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Institute of Human Genetics, University Hospital Erlangen, Erlangen, Germany
A Heather Eliassen Harvard Medical School, Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA
Carolina Ellberg Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden
Christoph Engel University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany University of Leipzig, LIFE - Leipzig Research Centre for Civilization Diseases, Leipzig, Germany
Mikael Eriksson Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
D Gareth Evans University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, UK St Marys Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester Centre for Genomic Medicine, Manchester, UK
Jonine Figueroa National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA The University of Edinburgh Medical School, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK Cancer Research UK Edinburgh Centre, Edinburgh, UK
Dieter Flesch-Janys University Medical Centre Hamburg-Eppendorf, Institute for Medical Biometrics and Epidemiology, Hamburg, Germany University Medical Centre Hamburg-Eppendorf, Department of Cancer Epidemiology, Clinical Cancer Registry, Hamburg, Germany
Henrik Flyger Copenhagen University Hospital, Department of Breast Surgery, Herlev and Gentofte Hospital, Herlev, Denmark
Marike Gabrielson Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
Manuela Gago-Dominguez Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Genomic Medicine Group, Galician Foundation of Genomic Medicine, SERGAS, Santiago de Compostela, Spain University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
Eva Galle VIB, VIB Center for Cancer Biology, Leuven, Belgium University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium
Susan M Gapstur American Cancer Society, Epidemiology Research Program, Atlanta, GA, USA
Montserrat García-Closas National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK
José A García-Sáenz Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Medical Oncology Department, Hospital Cl'nico San Carlos, Madrid, Spain
Mia M Gaudet American Cancer Society, Epidemiology Research Program, Atlanta, GA, USA
Angela George The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK The Royal Marsden NHS Foundation Trust, Cancer Genetics Unit, London, UK
Vassilios Georgoulias University Hospital of Heraklion, Department of Medical Oncology, Heraklion, Greece
Graham G Giles Cancer Council Victoria, Cancer Epidemiology & Intelligence Division, Melbourne, VIC, Australia The University of Melbourne, Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, Melbourne, VIC, Australia Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, VIC, Australia
Gord Glendon Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, Canada
David E Goldgar Huntsman Cancer Institute, University of Utah School of Medicine, Department of Dermatology, Salt Lake City, UT, USA
Anna González-Neira Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain
Grethe I Grenaker Alnæs Oslo University Hospital-Radiumhospitalet, Department of Cancer Genetics, Institute for Cancer Research, Oslo, Norway
Mervi Grip University of Oulu, Department of Surgery, Oulu University Hospital, Oulu, Finland
Pascal Guénel INSERM, University Paris-Sud, University Paris-Saclay, Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), Villejuif, France
Lothar Haeberle Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Centre Erlangen-EMN, Department of Gynaecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany
Eric Hahnen University Hospital of Cologne, Centre for Hereditary Breast and Ovarian Cancer, Cologne, Germany University of Cologne, Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany
Christopher A Haiman University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
Niclas Håkansson Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
Per Hall Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden South General Hospital, Department of Oncology, Stockholm, Sweden
Ute Hamann German Cancer Research Centre (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany
Susan Hankinson University of Massachusetts, Amherst, Department of Biostatistics & Epidemiology, Amherst, MA, USA
Elaine F Harkness University of Manchester, Manchester Academic Health Science Centre, Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester, UK Wythenshawe Hospital, Manchester University NHS Foundation Trust, Nightingale Breast Screening Centre, Manchester, UK Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Unit, Manchester, UK
Patricia A Harrington University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
Steven N Hart Mayo Clinic, Department of Health Sciences Research, Rochester, MN, USA
Jaana M Hartikainen University of Eastern Finland, Translational Cancer Research Area, Kuopio, Finland University of Eastern Finland, Institute of Clinical Medicine, Pathology and Forensic Medicine, Kuopio, Finland Kuopio University Hospital, Imaging Centre, Department of Clinical Pathology, Kuopio, Finland
Alexander Hein University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany
Peter Hillemanns Hannover Medical School, Gynaecology Research Unit, Hannover, Germany
Louise Hiller University of Warwick, Warwick Clinical Trials Unit, Coventry, UK
Bernd Holleczek Saarland Cancer Registry, Saarbruecken, Germany
Antoinette Hollestelle Erasmus MC Cancer Institute, Department of Medical Oncology, Family Cancer Clinic, Rotterdam, The Netherlands
Maartje J Hooning Erasmus MC Cancer Institute, Department of Medical Oncology, Family Cancer Clinic, Rotterdam, The Netherlands
Robert N Hoover National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
John L Hopper The University of Melbourne, Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, Melbourne, VIC, Australia
Anthony Howell University of Manchester, Institute of Cancer studies, Manchester, UK
Guanmengqian Huang German Cancer Research Centre (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany
Keith Humphreys Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
David J Hunter Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA Harvard T.H. Chan School of Public Health, Program in Genetic Epidemiology and Statistical Genetics, Boston, MA, USA University of Oxford, Nuffield Department of Population Health, Oxford, UK
Wolfgang Janni Cancer Research UK Edinburgh Centre, Edinburgh, UK
Esther M John Cancer Prevention Institute of California, Department of Epidemiology, Fremont, CA, USA Stanford University School of Medicine, Department of Health Research and Policy - Epidemiology, Stanford, CA, USA Stanford University School of Medicine, Department of Biomedical Data Science, Stanford, CA, USA
Michael E Jones Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK
Arja Jukkola-Vuorinen Tampere University Hospital, Department of Oncology, Tampere, Finland
Audrey Jung German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany
Rudolf Kaaks German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany
Maria Kabisch German Cancer Research Centre (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany
Katarzyna Kaczmarek Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
Michael J Kerin National University of Ireland, Surgery, School of Medicine, Galway, Ireland
Sofia Khan University of Helsinki, Department of Obstetrics and Gynaecology, Helsinki University Hospital, Helsinki, Finland
Elza Khusnutdinova Ufa Scientific Center of Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia Bashkir State University, Department of Genetics and Fundamental Medicine, Ufa, Russia
Johanna I Kiiski University of Helsinki, Department of Obstetrics and Gynaecology, Helsinki University Hospital, Helsinki, Finland
Cari M Kitahara National Cancer Institute, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
Julia A Knight Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Prosserman Centre for Population Health Research, Toronto, ON, Canada University of Toronto, Division of Epidemiology, Dalla Lana School of Public Health, Toronto, ON, Canada
Yon-Dschun Ko Johanniter Krankenhaus, Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Bonn, Germany
Linetta B Koppert Erasmus MC Cancer Institute, Department of Surgical Oncology, Family Cancer Clinic, Rotterdam, The Netherlands
Veli-Matti Kosma University of Eastern Finland, Translational Cancer Research Area, Kuopio, Finland University of Eastern Finland, Institute of Clinical Medicine, Pathology and Forensic Medicine, Kuopio, Finland Kuopio University Hospital, Imaging Centre, Department of Clinical Pathology, Kuopio, Finland
Peter Kraft Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA Harvard T.H. Chan School of Public Health, Program in Genetic Epidemiology and Statistical Genetics, Boston, MA, USA
Vessela N Kristensen Oslo University Hospital-Radiumhospitalet, Department of Cancer Genetics, Institute for Cancer Research, Oslo, Norway University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway Department of Research, Vestre Viken Hospital, Drammen, Norway; Section for Breast- and Endocrine Surgery, Department of Cancer, Division of Surgery, Cancer and Transplantation Medicine, Oslo University Hospital-Ullevål, Oslo, Norway Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway Department of Pathology at Akershus University hospital, Lørenskog, Norway Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway Department of Oncology, Division of Surgery and Cancer and Transplantation Medicine, Oslo University Hospital-Radiumhospitalet, Oslo, Norway National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway Department of Oncology, Akershus University Hospital, Lørenskog, Norway Breast Cancer Research Consortium, Oslo University Hospital, Oslo, Norway
Ute Krüger Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden
Tabea Kühl University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), Hamburg, Germany
Diether Lambrechts VIB, VIB Center for Cancer Biology, Leuven, Belgium University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium
Loic Le Marchand University of Hawaii Cancer Center, Epidemiology Program, Honolulu, HI, USA
Eunjung Lee University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
Flavio Lejbkowicz Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel
Lian Li Tianjin Medical University Cancer Institute and Hospital, Department of Epidemiology, Tianjin, China
Annika Lindblom Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden
Sara Lindström University of Washington School of Public Health, Department of Epidemiology, Seattle, WA, USA Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA, USA
Martha Linet National Cancer Institute, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
Jolanta Lissowska M. Sklodowska-Curie Cancer Centre, Oncology Institute, Department of Cancer Epidemiology and Prevention, Warsaw, Poland
Wing-Yee Lo Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany University of Tübingen, Tübingen, Germany
Sibylle Loibl GmbH, German Breast Group, Neu Isenburg, Germany
Jan Lubiński Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
Michael P Lux Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Centre Erlangen-EMN, Department of Gynaecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany
Robert J MacInnis Cancer Council Victoria, Cancer Epidemiology & Intelligence Division, Melbourne, VIC, Australia The University of Melbourne, Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, Melbourne, VIC, Australia
Melanie Maierthaler German Cancer Research Center (DKFZ), Molecular Epidemiology Group, C080, Heidelberg, Germany
Tom Maishman University of Southampton, Southampton Clinical Trials Unit, Faculty of Medicine, Southampton, UK University of Southampton, Cancer Sciences Academic Unit, Faculty of Medicine, Southampton, UK
Enes Makalic The University of Melbourne, Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, Melbourne, VIC, Australia
Arto Mannermaa University of Eastern Finland, Translational Cancer Research Area, Kuopio, Finland University of Eastern Finland, Institute of Clinical Medicine, Pathology and Forensic Medicine, Kuopio, Finland Kuopio University Hospital, Imaging Centre, Department of Clinical Pathology, Kuopio, Finland
Mehdi Manoochehri German Cancer Research Centre (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany
Siranoush Manoukian Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), Unit of Medical Genetics, Department of Medical Oncology and Haematology, Milan, Italy
Sara Margolin Karolinska Institutet, Department of Clinical Science and Education, Sšdersjukhuset, Stockholm, Sweden
Maria Elena Martinez University of California San Diego, Moores Cancer Center, La Jolla, CA, USA University of California San Diego, Department of Family Medicine and Public Health, La Jolla, CA, USA
Dimitrios Mavroudis University Hospital of Heraklion, Department of Medical Oncology, Heraklion, Greece
Catriona McLean The Alfred Hospital, Anatomical Pathology, Melbourne, VIC, Australia
Alfons Meindl Ludwig Maximilian University of Munich, Department of Gynaecology and Obstetrics, Munich, Germany
Pooja Middha German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany University of Heidelberg, Faculty of Medicine, Heidelberg, Germany
Nicola Miller National University of Ireland, Surgery, School of Medicine, Galway, Ireland
Roger L Milne Cancer Council Victoria, Cancer Epidemiology & Intelligence Division, Melbourne, VIC, Australia The University of Melbourne, Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, Melbourne, VIC, Australia
Fernando Moreno Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Medical Oncology Department, Hospital Cl'nico San Carlos, Madrid, Spain
Anna Marie Mulligan University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada University Health Network, Laboratory Medicine Program, Toronto, ON, Canada
Claire Mulot INSERM UMR-S1147, Université Paris Sorbonne Cité, Paris, France
Rami Nassir University of California Davis, Department of Biochemistry and Molecular Medicine, Davis, CA, USA
Susan L Neuhausen Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, CA, USA
William T Newman University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, UK St Marys Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester Centre for Genomic Medicine, Manchester, UK
Sune F Nielsen Copenhagen University Hospital, Copenhagen General Population Study, Herlevand Gentofte Hospital, Herlev, Denmark Copenhagen University Hospital, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark
Børge G Nordestgaard Copenhagen University Hospital, Copenhagen General Population Study, Herlevand Gentofte Hospital, Herlev, Denmark Copenhagen University Hospital, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark
Aaron Norman Mayo Clinic, Department of Health Sciences Research, Rochester, MN, USA
Håkan Olsson Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden
Nick Orr Queen's University Belfast, Centre for Cancer Research and Cell Biology, Belfast, Ireland, UK
V Shane Pankratz University of New Mexico, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
Tjoung-Won Park-Simon Hannover Medical School, Gynaecology Research Unit, Hannover, Germany
Jose I A Perez Hospital Monte Naranco, Servicio de Cirug'a General y Especialidades, Oviedo, Spain
Clara Pérez-Barrios Hospital Universitario Puerta de Hierro, Medical Oncology Department, Madrid, Spain
Paolo Peterlongo The FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, IFOM, Milan, Italy
Christos Petridis King's College London, Research Oncology, Guy's Hospital, London, UK
Mila Pinchev Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel
Karoliona Prajzendanc Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
Ross Prentice Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Seattle, WA, USA
Nadege Presneau University of Westminster, Department of Biomedical Sciences, Faculty of Science and Technology, London, UK
Darya Prokofieva Bashkir State University, Department of Genetics and Fundamental Medicine, Ufa, Russia
Katri Pylkäs University of Oulu, Laboratory of Cancer Genetics and Tumour Biology, Cancer and Translational Medicine Research Unit, Biocentre Oulu, Oulu, Finland Northern Finland Laboratory Centre Oulu, Laboratory of Cancer Genetics and Tumour Biology, Oulu, Finland
Brigitte Rack Ludwig Maximilian University of Munich, Department of Gynaecology and Obstetrics, Munich, Germany
Paolo Radice Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Milan, Italy
Dhanya Ramachandran Hannover Medical School, Gynaecology Research Unit, Hannover, Germany
Gadi Rennert Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel
Hedy S Rennert Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel
Valerie Rhenius University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
Atocha Romero Hospital Universitario Puerta de Hierro, Medical Oncology Department, Madrid, Spain
Rebecca Roylance UCLH Foundation Trust, Department of Oncology, London, UK
Emmanouil Saloustros University Hospital of Larissa, Department of Oncology, Larissa, Greece
Elinor J Sawyer King's College London, Research Oncology, Guy's Hospital, London, UK
Daniel F Schmidt The University of Melbourne, Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, Melbourne, VIC, Australia
Rita K Schmutzler University Hospital of Cologne, Centre for Hereditary Breast and Ovarian Cancer, Cologne, Germany University of Cologne, Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany
Andreas Schneeweiss University of Heidelberg, Department of Obstetrics and Gynecology, Heidelberg, Germany University of Heidelberg, National Centre for Tumour Diseases, Heidelberg, Germany
Minouk J Schoemaker The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK
Fredrick Schumacher Case Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland, OH, USA
Lukas Schwentner Cancer Research UK Edinburgh Centre, Edinburgh, UK
Rodney J Scott John Hunter Hospital, Division of Molecular Medicine, Pathology North, Newcastle, NSW, Australia University of Newcastle, Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy, Faculty of Health, Callaghan, NSW, Australia John Hunter Hospital, Hunter Medical Research Institute, Newcastle, NSW, Australia University of Newcastle, Centre for Information Based Medicine, Callaghan, Newcastle, NSW, Australia
Christopher Scott Mayo Clinic, Department of Health Sciences Research, Rochester, MN, USA
Caroline Seynaeve Erasmus MC Cancer Institute, Department of Medical Oncology, Family Cancer Clinic, Rotterdam, The Netherlands
Mitul Shah University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
Jacques Simard Centre Hospitalier Universitaire de Québec - Université Laval Research Centre, Genomics Centre, Québec City, QC, Canada
Ann Smeets University Hospitals Leuven, Department of Surgical Oncology, Leuven, Belgium
Christof Sohn University of Heidelberg, National Centre for Tumour Diseases, Heidelberg, Germany
Melissa C Southey Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, Victoria, Australia The University of Melbourne, Department of Clinical Pathology, Melbourne, VIC, Australia
Anthony J Swerdlow The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK The Institute of Cancer Research, Division of Breast Cancer Research, London, UK
Aline Talhouk BC Cancer Agency and University of British Columbia, British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver General Hospital, Vancouver, BC, Canada University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada University of British Columbia, Department of Obstetrics and Gynaecology, Vancouver, BC, Canada
Rulla M Tamimi Harvard Medical School, Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA Harvard T.H. Chan School of Public Health, Program in Genetic Epidemiology and Statistical Genetics, Boston, MA, USA
William J Tapper University of Southampton, Faculty of Medicine, Southampton, UK
Manuel R Teixeira Portuguese Oncology Institute, Department of Genetics, Porto, Portugal University of Porto, Biomedical Sciences Institute (ICBAS), Porto, Portugal
Maria Tengström University of Eastern Finland, Translational Cancer Research Area, Kuopio, Finland Kuopio University Hospital, Cancer Centre, Kuopio, Finland University of Eastern Finland, Institute of Clinical Medicine, Oncology, Kuopio, Finland
Mary Beth Terry Columbia University, Department of Epidemiology, Mailman School of Public Health, New York, NY, USA
Kathrin Thöne University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), Hamburg, Germany
Rob A E M Tollenaar Leiden University Medical Centre, Department of Surgery, Leiden, The Netherlands
Ian Tomlinson University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, UK University of Oxford, Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, Oxford, UK
Diana Torres German Cancer Research Centre (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany Pontificia Universidad Javeriana, Institute of Human Genetics, Bogota, Colombia
Thérèse Truong INSERM, University Paris-Sud, University Paris-Saclay, Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), Villejuif, France
Constance Turman Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA
Clare Turnbull The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK
Hans-Ulrich Ulmer Frauenklinik der Stadtklinik Baden-Baden, Baden-Baden, Germany
Michael Untch Helios Clinics Berlin-Buch, Department of Gynaecology and Obstetrics, Berlin, Germany
Celine Vachon Mayo Clinic, Department of Health Sciences Research, Rochester, MN, USA
Christi J van Asperen Leiden University Medical Centre, Department of Clinical Genetics, Leiden, The Netherlands
Ans M W van den Ouweland Erasmus University Medical Centre, Department of Clinical Genetics, Rotterdam, The Netherlands
Elke M van Veen University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, UK St Marys Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester Centre for Genomic Medicine, Manchester, UK
Camilla Wendt Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden
Alice S Whittemore Stanford University School of Medicine, Department of Health Research and Policy - Epidemiology, Stanford, CA, USA Stanford University School of Medicine, Department of Biomedical Data Science, Stanford, CA, USA
Walter Willett Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA Harvard T.H. Chan School of Public Health, Department of Nutrition, Boston, MA, USA Brigham and Women's Hospital and Harvard Medical School, Channing Division of Network Medicine, Boston, MA, USA
Robert Winqvist University of Oulu, Laboratory of Cancer Genetics and Tumour Biology, Cancer and Translational Medicine Research Unit, Biocentre Oulu, Oulu, Finland Northern Finland Laboratory Centre Oulu, Laboratory of Cancer Genetics and Tumour Biology, Oulu, Finland
Alicja Wolk Karolinska Institutet, Department of Environmental Medicine, Division of Nutritional Epidemiology, Stockholm, Sweden
Xiaohong R Yang National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
Yan Zhang German Cancer Research Center (DKFZ), Division of Clinical Epidemiology and Aging Research, Heidelberg, Germany German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
Douglas F Easton University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
Peter A Fasching University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, Los Angeles, CA, USA
Heli Nevanlinna University of Helsinki, Department of Obstetrics and Gynaecology, Helsinki University Hospital, Helsinki, Finland
Diana M Eccles University of Southampton, Cancer Sciences Academic Unit, Faculty of Medicine, Southampton, UK
Paul D P Pharoah University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
Marjanka K Schmidt The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, The Netherlands The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Division of Psychosocial Research and Epidemiology, Amsterdam, The Netherlands

Collapse

Zych D, Slodek A, Krompiec S, Malarz K, Mrozek-Wilczkiewicz A, Musiol R. 4′-Phenyl-2,2′:6′,2′′-terpyridine Derivatives Containing 1-Substituted-2,3-Triazole Ring: Synthesis, Characterization and Anticancer Activity. ChemistrySelect 2018. [DOI: 10.1002/slct.201801204] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]

Phenotypic and genotypic characterization of antioxidant enzyme system in human population exposed to radiation from mobile towers. Mol Cell Biochem 2017;440:1-9. [PMID: 28819931 DOI: 10.1007/s11010-017-3150-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 08/05/2017] [Indexed: 12/13/2022]

Wang C, Liu Y, Zhou J, Ye L, Chen N, Zhu M, Ji Y. There is no relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival. Mol Clin Oncol 2017;7:579-590. [PMID: 29046792 DOI: 10.3892/mco.2017.1376] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2017] [Accepted: 07/21/2017] [Indexed: 02/05/2023] Open

Verma A, Ahmed B, Anwar F, Rahman M, Patel DK, Kaithwas G, Rani R, Bhatt PC, Kumar V. Novel glycoside from Wedelia calendulacea inhibits diethyl nitrosamine-induced renal cancer via downregulating the COX-2 and PEG2 through nuclear factor-κB pathway. Inflammopharmacology 2017;25:159-175. [DOI: 10.1007/s10787-017-0310-y] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 01/04/2017] [Indexed: 12/27/2022]

Kong X, Li Z, Li X. GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis. Cancer Chemother Pharmacol 2016;78:1163-1173. [PMID: 27785604 DOI: 10.1007/s00280-016-3173-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 10/12/2016] [Indexed: 01/22/2023]

Abstract

Several studies have investigated the effects of polymorphisms in the GSTP1, GSTT1, and GSTM1 genes on responsiveness to chemotherapy in breast cancer, but the results have been inconsistent. The aim of this study was to determine the association between polymorphisms of GSTP1, GSTT1, and GSTM1 genes and response to chemotherapy in patients with breast cancer. The relevant studies were retrieved from PubMed, Embase, ISI Web of Knowledge, China National Knowledge Infrastructure, and Wanfang databases. The articles evaluating the correlations between response to chemotherapy and GSTP1, GSTT1, and GSTM1 polymorphisms in breast cancer patients were comprehensively reviewed. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to measure the strength of the associations. These associations were assessed with the χ ² test in this meta-analysis. Subgroup analysis by chemotherapy protocol and ethnicity were conducted to explore the source of heterogeneity among studies. A total of 14 articles with 31 studies involving GSTP1, GSTT1, and GSTM1 polymorphisms with response to chemotherapy were identified in the final meta-analysis. In the overall analysis, a significant association of GSTM1-present/GSTM1-null polymorphism with responsiveness to chemotherapy was observed in breast cancer patients (OR 0.74, CI 0.60-0.92, P = 0.006), whereas the GSTT1-present/GSTT1-null and GSTP1rs1695 polymorphisms were not significantly associated with clinical response to chemotherapy. The subgroup analysis by chemotherapy protocol indicated that the patients who harboring GSTP1rs1695 AA or AG variant had a higher response rate to anthracycline-based chemotherapy than those carrying GSTP1rs1695 GG variant [AA vs. GG: OR 0.48, CI 0.29-0.80, P < 0.05; AA vs. AG: OR 0.60, CI 0.43-0.83, P < 0.05; A vs. G: OR 0.60, CI 0.47-0.77, P < 0.05; AA vs. (AG + GG): OR 0.56, CI 0.42-0.76, P < 0.05; (AA + AG) vs. GG: OR 0.57, CI 0.34-0.94, P < 0.05]. In addition, the heterogeneity existed among studies for GSTP1 polymorphism, while no obvious heterogeneity was detected for GSTT1 and GSTM1 polymorphisms. And the heterogeneity present in different studies, evaluating the association of GSTP1 polymorphism with response to anthracycline-based chemotherapy, disappeared in breast cancer patients after subgroup analysis by chemotherapy regimen was performed. In conclusion, this meta-analysis suggested that GSTP1rs1695 and GSTM1-present/GSTM1-null polymorphisms could be considered as reliable predictors of response to anthracycline-based chemotherapy in patients with breast cancer.

Collapse

The Role of Catalase C262T Gene Polymorphism in the Susceptibility and Survival of Cancers. Sci Rep 2016;6:26973. [PMID: 27225983 PMCID: PMC4880922 DOI: 10.1038/srep26973] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Accepted: 05/10/2016] [Indexed: 02/07/2023] Open

Gillies PJ, Krul ES. Using genetic variation to optimize nutritional preemption. J Nutr 2007;137:270S-274S. [PMID: 17182839 DOI: 10.1093/jn/137.1.270s] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open